| Revenue growth | Revenue ₹23.29 Cr: +62% QoQ, -23% YoY; recovering from weak Q1. |
|---|---|
| Margins | EBITDA margin 17% vs 23% Q1 and 32% Q2 FY26; contracting. |
| Demand visibility | European demand subdued; domestic pivot; RFQs rising; no volume outlook. |
| Management confidence | Balanced; admits recovery incomplete; optimism largely qualitative. |
Growth
Revenue +62% QoQ off weak Q1, but -23% YoY. EBITDA -59% YoY; PAT -67% YoY.
Outlook
No revenue or margin guidance given. Commercial supply from Q1 FY28; ~80% plant utilisation at peak, in three years.
Risks
Opex +76% vs revenue +62%; European order deferrals; inventory build-up; no firm commercial supply date beyond Q1 FY28.
Earnings Call Transcript filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹605.80
- Market cap
- ₹777.7 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 64.2×Sector 49.0×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q2FY27 revenue ₹23.29 Cr (-23% YoY, +62% QoQ), EBITDA margin 16.9%, PAT ₹1.63 Cr (-67% YoY). Sequential recovery; CRAMS and new products progressing.
Shree Ganesh Remedies Results Update
Shree Ganesh Remedies released a press release on Q2 and H1 FY27 unaudited results, with Q2 revenue of ₹23.29 Crore, down 23% year-on-year. PAT fell 67% to ₹1.63 Crore.
Shree Ganesh Remedies Q2 FY27 Results: Net Profit ₹1.6 Cr, Down 68.0% YoY
Shree Ganesh Remedies' board approved unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. Revenue from operations for the half year was Rs 3,765.47 lakhs, down from Rs 5,498.29 lakhs a year earlier.
- Key figure
- Net profit ₹1.6 Cr · -68.0% YoY
Shree Ganesh Remedies Board Meeting Date
Shree Ganesh Remedies Ltd notified BSE of a board meeting on October 31, 2026, to consider unaudited standalone and consolidated results for the quarter ended September 2026. Trading window remains closed until 48 hours after the results declaration.
Shree Ganesh Remedies Other Announcement
Shree Ganesh Remedies Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Shree Ganesh Remedies Management Change
Shree Ganesh Remedies Ltd has announced the resignation of Mr. Aditya Vikrambhai Patel as Company Secretary and the appointment of Ms. Akanksha as his successor.